Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979796857> ?p ?o ?g. }
- W2979796857 abstract "Abstract Abstract 1746 Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (WHO) classification, that provides a guideline to distinguish ET from early/prefibrotic primary myelofibrosis. These two conditions differ in term of disease evolution and survival (Barbui et al, J. Clin. Oncol. 2011). To design a prognostic model for survival in WHO-defined ET (International Prognostic Score for Essential Thrombocythemia, IPSET), we studied 891 patients with strict WHO diagnostic criteria. Demographics have been presented elsewhere (Barbui et al, J. Clin. Oncol. 2011). We tested the prognostic impact on survival of age, prior thrombosis, leukocyte count, platelet count, hemoglobin level, JAK mutational status, splenomegaly. Harrell's C concordance statistics were used to set the best cutoff levels of continuous variables in order to predict survival. Univariate Cox proportional hazard regression showed that age over 60 years (P<.0001), leukocyte count greater than 11 x109/L (P<.0001), anemia (P=.04), platelet count greater than 1000 x109/L (P<.004) and prior history of thrombosis (P< 0001) were significant risk factors for survival. Age over 60 years (hazard ratio-HR- 6.5, 95% CI: 3.9–10.7; P<.0001), leukocyte count greater than 11 × 109/L (HR: 3.1, 95% CI: 2–4.7; P<.0001) and prior history of thrombosis (HR: 2.9, 95% CI: 1.9–4.5; P< 0001) retained statistical significance on survival by multivariable analysis and were included in the new prognostic model. We assigned each factor an integer weight close to the corresponding HR in the multivariable Cox regression: weight 2 for age over 60 years; weight 1 for leukocyte count greater than 11 x109/L and for prior thrombosis. Finally, we defined the IPSET score by allocating patients into three risk categories with significantly different survival according to the sum of weights: low risk (sum of weights=0; n= 342; median survival not reached), intermediate risk (sum=1-2; N=374; median survival 24.5 years), and high risk (sum=3-4, n=158; median survival 13.8 years). Fisher exact test did not reveal a difference in the distribution of the causes of death among IPSET categories. We validated the model in two independent cohorts: one from Germany (132 WHO-defined ET) and another from France (234 ET patients not strictly diagnosed according to WHO). Log rank test and Cox regression showed significant differences in term of survival among IPSET categories in both series. Finally, we designed an age-specific IPSET model for patients younger than 60 years (IPSET-y). Using the same methodology, we found that age over 45 years (weight 2), leukocyte count greater than 11 × 109/L (weight 1) and prior history of thrombosis (weight 1) were independent risk factors for survival. IPSET-y defined three risk categories (LR, sum=0; IR, sum=1-2; HR, sum=3–4) with a median survival not reached in LR and IR, and of 22.3 years in HR. In conclusion, IPSET, based on age over 60 years, leukocyte count greater than 11 x109/L and history of thrombosis allows prognostic assessment of WHO-defined ET. The validation process makes IPSET applicable in all patients phenotypically appearing as ET. IPSET models may be useful for treatment decision-making. Disclosures: Vannucchi: Italfarmaco: Consultancy; Novartis: Honoraria. Gisslinger:AOP Orphan Pharmaceuticals AG: Research Funding." @default.
- W2979796857 created "2019-10-18" @default.
- W2979796857 creator A5002643270 @default.
- W2979796857 creator A5008437556 @default.
- W2979796857 creator A5009381933 @default.
- W2979796857 creator A5009672509 @default.
- W2979796857 creator A5013529815 @default.
- W2979796857 creator A5014707543 @default.
- W2979796857 creator A5016216479 @default.
- W2979796857 creator A5021534296 @default.
- W2979796857 creator A5027542527 @default.
- W2979796857 creator A5029918265 @default.
- W2979796857 creator A5036871832 @default.
- W2979796857 creator A5037291158 @default.
- W2979796857 creator A5046772202 @default.
- W2979796857 creator A5046864041 @default.
- W2979796857 creator A5047994754 @default.
- W2979796857 creator A5048466694 @default.
- W2979796857 creator A5049331182 @default.
- W2979796857 creator A5050011235 @default.
- W2979796857 creator A5052112147 @default.
- W2979796857 creator A5057447510 @default.
- W2979796857 creator A5062082543 @default.
- W2979796857 creator A5063853781 @default.
- W2979796857 creator A5069072959 @default.
- W2979796857 creator A5071031452 @default.
- W2979796857 creator A5072484806 @default.
- W2979796857 creator A5072657141 @default.
- W2979796857 creator A5073807974 @default.
- W2979796857 creator A5082953818 @default.
- W2979796857 creator A5091196790 @default.
- W2979796857 date "2011-11-18" @default.
- W2979796857 modified "2023-10-01" @default.
- W2979796857 title "A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)" @default.
- W2979796857 doi "https://doi.org/10.1182/blood.v118.21.1746.1746" @default.
- W2979796857 hasPublicationYear "2011" @default.
- W2979796857 type Work @default.
- W2979796857 sameAs 2979796857 @default.
- W2979796857 citedByCount "2" @default.
- W2979796857 countsByYear W29797968572016 @default.
- W2979796857 crossrefType "journal-article" @default.
- W2979796857 hasAuthorship W2979796857A5002643270 @default.
- W2979796857 hasAuthorship W2979796857A5008437556 @default.
- W2979796857 hasAuthorship W2979796857A5009381933 @default.
- W2979796857 hasAuthorship W2979796857A5009672509 @default.
- W2979796857 hasAuthorship W2979796857A5013529815 @default.
- W2979796857 hasAuthorship W2979796857A5014707543 @default.
- W2979796857 hasAuthorship W2979796857A5016216479 @default.
- W2979796857 hasAuthorship W2979796857A5021534296 @default.
- W2979796857 hasAuthorship W2979796857A5027542527 @default.
- W2979796857 hasAuthorship W2979796857A5029918265 @default.
- W2979796857 hasAuthorship W2979796857A5036871832 @default.
- W2979796857 hasAuthorship W2979796857A5037291158 @default.
- W2979796857 hasAuthorship W2979796857A5046772202 @default.
- W2979796857 hasAuthorship W2979796857A5046864041 @default.
- W2979796857 hasAuthorship W2979796857A5047994754 @default.
- W2979796857 hasAuthorship W2979796857A5048466694 @default.
- W2979796857 hasAuthorship W2979796857A5049331182 @default.
- W2979796857 hasAuthorship W2979796857A5050011235 @default.
- W2979796857 hasAuthorship W2979796857A5052112147 @default.
- W2979796857 hasAuthorship W2979796857A5057447510 @default.
- W2979796857 hasAuthorship W2979796857A5062082543 @default.
- W2979796857 hasAuthorship W2979796857A5063853781 @default.
- W2979796857 hasAuthorship W2979796857A5069072959 @default.
- W2979796857 hasAuthorship W2979796857A5071031452 @default.
- W2979796857 hasAuthorship W2979796857A5072484806 @default.
- W2979796857 hasAuthorship W2979796857A5072657141 @default.
- W2979796857 hasAuthorship W2979796857A5073807974 @default.
- W2979796857 hasAuthorship W2979796857A5082953818 @default.
- W2979796857 hasAuthorship W2979796857A5091196790 @default.
- W2979796857 hasConcept C10515644 @default.
- W2979796857 hasConcept C126322002 @default.
- W2979796857 hasConcept C142724271 @default.
- W2979796857 hasConcept C143998085 @default.
- W2979796857 hasConcept C144301174 @default.
- W2979796857 hasConcept C160798450 @default.
- W2979796857 hasConcept C207103383 @default.
- W2979796857 hasConcept C2778837598 @default.
- W2979796857 hasConcept C2779788118 @default.
- W2979796857 hasConcept C2780007613 @default.
- W2979796857 hasConcept C2780076729 @default.
- W2979796857 hasConcept C2780182762 @default.
- W2979796857 hasConcept C2781057849 @default.
- W2979796857 hasConcept C2993277928 @default.
- W2979796857 hasConcept C3019894029 @default.
- W2979796857 hasConcept C38180746 @default.
- W2979796857 hasConcept C44249647 @default.
- W2979796857 hasConcept C50382708 @default.
- W2979796857 hasConcept C71924100 @default.
- W2979796857 hasConcept C89560881 @default.
- W2979796857 hasConceptScore W2979796857C10515644 @default.
- W2979796857 hasConceptScore W2979796857C126322002 @default.
- W2979796857 hasConceptScore W2979796857C142724271 @default.
- W2979796857 hasConceptScore W2979796857C143998085 @default.
- W2979796857 hasConceptScore W2979796857C144301174 @default.
- W2979796857 hasConceptScore W2979796857C160798450 @default.
- W2979796857 hasConceptScore W2979796857C207103383 @default.
- W2979796857 hasConceptScore W2979796857C2778837598 @default.
- W2979796857 hasConceptScore W2979796857C2779788118 @default.
- W2979796857 hasConceptScore W2979796857C2780007613 @default.